Sure. The idea of creating patent and tax-based incentives for developers to go after orphan drugs, so the niche indication, has been a dramatic success from every perspective in the EU and the U.S. The U.S. originated it in 1983. In the EU I think it was in 2000 they implemented it.
What it does is provide an incentive for developers to go after very niche markets. It has proven to be an area where developers can actively prove out the effectiveness of a drug. It's critical for those patients, obviously, because you find yourself suffering from a particular orphan disease and there's nothing out there and there's no economic incentive, candidly, for a large drug developer because they tend to have bigger fish to fry. They go after larger markets than—